SXLV:SW:SW-SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) (USD)

ETF | Others |

Last Closing

USD 40.925

Change

-0.32 (-0.76)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

N/A

USD 1,244,681.59B
SPISI:SW UBS ETF (CH) - SPI® ESG (CHF)..

+0.02 (+0.10%)

USD 590,186.66B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.06 (+0.26%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.01 (+0.04%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

N/A

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-5.00 (-0.24%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-9.00 (-0.34%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.31 (+0.40%)

USD 131,872.43B

ETFs Containing SXLV:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.88% 37% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.88% 36% F 36% F
Trailing 12 Months  
Capital Gain -5.70% 12% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.70% 12% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.50% 51% F 54% F
Dividend Return 5.50% 51% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.03% 62% D 67% D+
Risk Adjusted Return 78.21% 55% F 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike